Advances in treatment formulations for acute myeloid leukemia - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Drug Discovery Today Biosilico Année : 2018

Advances in treatment formulations for acute myeloid leukemia

Résumé

Acute myeloid leukemia (AML) is the most common cause of leukemia-related mortality. The combination of cytarabine and anthracycline has been the gold standard of treatment over the past 40 years, but the distribution of the drugs in the body leads to severe adverse effects. Poor prognosis of older patients with AML is the consequence not only of comorbidities, but also of chemoresistance resulting from frequent secondary AML. Numerous strategies using nanotechnologies are in development to improve drug targeting, pharmacokinetics, administration route, chemoresistance, and adverse effects generally observed. Among the four new drugs approved for AML by the US Food and Drug Administration (FDA) in 2017, Vyxeos® is a novel liposomal formulation of historical AML drugs. Here, we review current AML treatments and discuss how the development of new formulations will change the therapeutic armamentarium.

Domaines

Cancer
Fichier principal
Vignette du fichier
ArticlemainEqAngers.pdf (734.74 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-01809889 , version 1 (07-06-2018)

Identifiants

Citer

Thomas Briot, Emilie Roger, Sylvain Thépot, Frédéric Lagarce. Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today Biosilico, 2018, Epub ahead of print. ⟨10.1016/j.drudis.2018.05.040⟩. ⟨inserm-01809889⟩
309 Consultations
1427 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More